December 18, 2007

Takeda Pharmaceutical Company Limited

Takeda Submitted an Application for an Additional Indication of BASEN^® in Japan for Prevention of Onset of Type 2 Diabetes in Patients with Impaired Glucose Tolerance

December 18, 2007, Osaka, Japan --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced its submission of an application to the Ministry of Health, Labour and Welfare in Japan for an additional indication of “BASEN^® Tablets 0.2” and “BASEN^® OD Tablets 0.2” (generic name: voglibose) for prevention of onset of type 2 diabetes in patients with impaired glucose tolerance (“IGT”).

BASEN was launched in 1994 in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus, with its mechanism of action of delaying the digestion and absorption of carbohydrate, resulting in improvement of postprandial hyperglycemia.

IGT is defined by the WHO (World Health Organization) as a state of higher than normal blood (or plasma) glucose concentration; fasting plasma glucose < 126 mg/dL AND 2 hour post 75g glucose drink of >= 140 mg/dL and 200 mg/dL. In the patients with IGT, the risk of both the onset of diabetes and cardiovascular diseases is increased, the dietary treatment and/or exercise therapy is conducted, however, there are cases in which sufficient effect has not been obtained.

“The number of patients population with diabetes is notably increasing in Japan, and the necessity of managing diabetic complications is becoming an important social issue,” said Masaomi Miyamoto, Ph.D., General Manager of Pharmaceutical Development Division of Takeda. “Once this application is approved, we will be able to offer a new treatment option of medicinal therapy for patients with IGT and healthcare providers who treat them.”

< About Basen^® in Japan >

INDICATIONS

Improvement of postprandial hyperglycemia in diabetes mellitus (However, BASEN^® Tablets should be used only when sufficient effect has not been obtained in patients already undergoing dietary treatment and/or exercise therapy, or when sufficient effect has not been obtained in patients who have been using oral hypoglycemic drugs or insulin preparations, in addition to dietary treatment and/or exercise therapy.)

DOSAGE AND ADMINISTRATION

Usually, for adults, BASEN® Tablets are orally administered in a single dose of 0.2 mg as voglibose, three times a day, just before each meal. If the effect is not sufficient enough, the single dose may be increased up to 0.3 mg, under close observation of the course of disease.

# # #